Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis

Optimizing the druggability of both native and AI-designed bioactive proteins is crucial for realizing their therapeutic potential. A key focus in designing protein-based therapeutics is improving their pharmacokinetic properties. However, a significant challenge is to preserve biological activity w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2024-12, Vol.376, p.1130-1142
Hauptverfasser:	Wang, Yapeng, Shen, Lei, Wang, Chengcheng, Dong, Yuanzhen, Hua, Haoju, Xu, Jun, Zhang, Ying, Huang, Hao, Huang, Zongqing, Zhao, Fei, Xu, Zhiru, Qiu, Yunliang, Lu, Jianguang, Ju, Dianwen, Feng, Jun
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Dimerization Druggability optimization Fibroblast growth factor 21 (FGF21) Fibroblast Growth Factors - administration & dosage Fibroblast Growth Factors - pharmacokinetics Fibroblast Growth Factors - therapeutic use Humans Lipidation Liver - drug effects Liver - metabolism Long-acting Male Mice, Inbred C57BL Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic steatohepatitis (NASH) Protein Multimerization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!